Ambelvist is an FDA approved gadolinium-based contrast agent indicated for contrast-enhanced magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and other body regions. As a next-generation, lower-dose MRI contrast agent, Ambelvist advances diagnostic imaging while supporting high-quality visualization across a broad range of clinical applications. For clinical trial and first-to-file teams, monitoring its market adoption, exclusivity timeline, and availability will be important, as it may become a relevant comparator in diagnostic imaging, radiology, and pharmaceutical development studies.